Clinical trials: Squamous Carcinoma
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Lymphoma, Advanced Solid Tumors
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.
- Trial name
- NCT04144140
- Testing
- E7766
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Squamous Cell Carcinoma of the Head and Neck
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
The purpose of the study is to capture the utilization of nivolumab among participants with squamous cell carcinoma of the head and neck (SCCHN) since its approval, and to describe the health related quality of life (HRQoL) among…
- Trial name
- VOLUME-PRO (NCT05068609)
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 509 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer Stage IV
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT06348199
- Testing
- SB27, Keytruda
- Where
- 93 sites in Bosnia and Herzegovina, Brazil and 12 more
- Volunteers
- 555 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Metastatic Non Small Cell Lung Cancer
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no…
- Trial name
- NCT05555732
- Testing
- Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed
- Where
- 260 sites in United States, Argentina and 27 more
- Volunteers
- 1,170 people
- Sponsor
- Daiichi Sankyo
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer
Study of XB010 in Subjects With Solid Tumors
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT06545331
- Testing
- XB010, Pembrolizumab
- Where
- 20 sites in United States, United Kingdom
- Volunteers
- 396 people
- Sponsor
- Exelixis
Actinic Keratosis
Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis
This Phase 2 clinical trial is a multi-center, randomized, double-blind, placebo-controlled, multiple-dose, parallel-cohort study to assess the efficacy, safety and tolerability of VDA-1102 in the treatment of actinic keratosis…
- Trial name
- NCT02844777
- Testing
- 5% VDA-1102, 10% VDA-1102
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Vidac Pharma
Non Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study of PX-866 and Docetaxel in Solid Tumors
Phase 1: To determine the maximally tolerated dose (MTD) or recommended dose (RD) and any potential efficacy of PX-866 in combination with docetaxel in patients with solid tumors.
- Trial name
- NCT01204099
- Testing
- Docetaxel, PX-866
- Where
- 33 sites in United States, Canada
- Volunteers
- 223 people
- Sponsor
- Cascadian Therapeutics Inc.
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01307267
- Testing
- PF-05082566, rituximab
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 190 people
- Sponsor
- Pfizer
Unspecified Adult Solid Tumor, Protocol Specific
A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
The purpose of this study is to determine the Maximum Tolerated Dose and the Dose-Limiting Toxicity of the drug to further evaluate safety and antitumor activity.
- Trial name
- NCT01631279
- Testing
- PR610
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 33 people
- Sponsor
- Proacta, Incorporated
Carcinoma, Non-Small-Cell Lung
A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
This study will evaluate the efficacy and safety of atezolizumab when given in combination with bevacizumab, investigator's choice of either paclitaxel or pemetrexed, and carboplatin compared with placebo given in combination…
- Trial name
- NCT04194203
- Testing
- Atezolizumab, Bevacizumab, Paclitaxel
- Where
- 23 sites in China
- Volunteers
- 305 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Carcinoma of Head and Neck
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
The primary objective of this study is to evaluate the efficacy of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line (1L) treatment in recurrent/metastatic PD-L1-positive squamous cell carcinoma of the…
- Trial name
- SKYSCRAPER-09 (NCT04665843)
- Testing
- Atezolizumab, Tiragolumab
- Where
- 47 sites in United States, Czechia and 11 more
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Head and Neck
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic…
- Trial name
- NCT06062420
- Testing
- Dostarlimab, Belrestotug, Nelistotug
- Where
- 108 sites in United States, Argentina and 18 more
- Volunteers
- 316 people
- Sponsor
- GlaxoSmithKline
Lung Squamous Cell Carcinoma
Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
The purpose of this study is to observe and confirm the safety, tolerance and cell pharmacokinetics of lentivirus-transduced CAR-GPC3 T cells (CAR-GPC3 T cells targeting GPC3)
- Trial name
- NCT02876978
- Testing
- CAR-GPC3 T Cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Advanced Esophageal Squamous Cell Carcinoma
Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
To investigate the efficacy and safety of TQB2618 injection combined Penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic esophageal squamous cell carcinoma compared with Penpulimab combined…
- Trial name
- NCT05834543
- Testing
- TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin, Penpulimab injection, Paclitaxel, Cisplatin, TQB2618 injection, Penpulimab injection, TQB3617capsules
- Where
- 10 sites in China
- Volunteers
- 34 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer, Cancer of the Head and Neck
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
The purpose of this study is to provide ZD1839 for those patients with locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV) or recurrent and/or metastatic squamous cell head and neck cancer…
- Trial name
- NCT00684385
- Testing
- ZD1839
- Where
- 34 sites in Germany, Hungary and 2 more
- Sponsor
- AstraZeneca
Squamous Cell Carcinoma
Patient Perspectives in Squamous Cell Carcinoma Clinical Trials
Clinical research participation has historically been heavily biased toward specific demographics. This study will invite several participants to gather a wide range of information on clinical trial experiences for squamous cell…
- Trial name
- NCT05929547
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Squamous Cell Carcinoma of the Cervix, Adenocarcinoma of the Cervix
Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application
They include patients who are candidates to complete concurrent treatment with endocavitary brachytherapy External radiation therapy + more QT based weekly cisplatin.
- Trial name
- NCT01639625
- Testing
- CIGB300
- Where
- Argentina
- Volunteers
- 18 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Advanced or Metastatic Solid Tumors, Lung Cancer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03665285
- Testing
- NC318
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- NextCure, Inc.
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent…
- Trial name
- NCT06496178
- Testing
- Petosemtamab, Investigator's Choice
- Where
- 193 sites in United States, Argentina and 22 more
- Volunteers
- 621 people
- Sponsor
- Merus B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.